Springer Nature
Browse
13195_2019_520_MOESM5_ESM.docx (19.96 kB)

Additional file 5: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Download (19.96 kB)
journal contribution
posted on 2019-08-07, 04:21 authored by Michael Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie Stone, Christine Furtek, Erin Mahoney, Jeffrey Cummings, Pierre Tariot, Paul Aisen, Bruno Vellas, Christopher Lines, David Michelson
Table S4. Mixed-Model Analyses for Neuropsychiatric Inventory Total Score. (DOCX 19 kb)

Funding

Merck

History